Categorynews

GlycoMimetics to Report First Quarter 2019 Financial Results on May 2, 2019

April 25, 2019 Off By BusinessWire

ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host a
conference call and webcast to report its first-quarter 2019 financial
results on Thursday, May 2, 2019, at 8:30 a.m. ET.

The dial-in number for the conference call is (844) 413-7154
(U.S. and Canada) or (216) 562-0466 (international) and entering
passcode 1096657. To access the live audio webcast, or the subsequent
archived recording, visit the “Investors – Events & Presentations”
section of the GlycoMimetics website at www.glycomimetics.com.
The webcast will be recorded and available for replay on the
GlycoMimetics website for 30 days following the call.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the
discovery and development of novel glycomimetic drugs to address unmet
medical needs resulting from diseases in which carbohydrate biology
plays a key role. GlycoMimetics’ most advanced drug candidate,
rivipansel, a pan-selectin antagonist, is being developed for the
treatment of vaso-occlusive crisis in sickle cell disease and is being
evaluated in a Phase 3 clinical trial being conducted by its strategic
collaborator, Pfizer. GlycoMimetics’ wholly owned drug candidate,
uproleselan, an E-selectin antagonist, was evaluated in a Phase 1/2
clinical trial as a potential treatment for AML and is being evaluated
across a range of patient populations including a company-sponsored
Phase 3 trial in relapsed/refractory AML. GlycoMimetics has also
completed a Phase 1 clinical trial with a third drug candidate,
GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is
located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Source: GlycoMimetics, Inc.